Adaptive Biotechnologies
The Senior Manager, Regulatory Affairs leads the development and execution of ex-US regulatory strategy for NGS-based in vitro diagnostic products, with a primary focus on EU IVDR and Health Canada markets. This role manages regulatory relationships with biopharma partners for companion diagnostic co-development programs and ensures alignment with US FDA frameworks. The position serves as a strategic partner to leadership, shaping international clinical and regulatory pathways while mentoring team members and driving cross-functional collaboration.
Headquarters
Seattle, Washington, United States
Company Size
501-1000 employees
Founded
2009
Adaptive Biotechnologies is a biotechnology company that uses immune system sequencing and machine learning to profile T-cell and B-cell receptors. It develops diagnostics and research tools for detecting disease, monitoring immune responses, and supporting drug discovery.
Adaptive Biotechnologies (NASDAQ:ADPT) Shares Gap Up - What's Next?
2 hours ago
Pier Capital LLC Sells 381,803 Shares of Adaptive Biotechnologies Corporation $ADPT
6 hours ago
Do Insider Sales Align With Adaptive Biotechnologies' (ADPT) MRD-Driven Momentum and Long-Term Strategy?
5 days ago
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Adaptive Biotechnologies.
17% above the average for this role
TD Cowen is Bullish on Adaptive Biotechnologies Corporation (ADPT)
3 weeks ago